This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
The use of trade names is for product identification purposes only and does not imply endorsement.
Harrison Swainston T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs 2006; 66(13): 1741–51
Kiefer F. Extended-release intramuscular naltrexone: a viewpoint. Drugs 2006; 66(13): 1752–4
Kranzler HR. Extended-release intramuscular naltrexone: a viewpoint. Drugs 2006; 66(13): 1752–4
Siegel S. Extended-release intramuscular naltrexone: a viewpoint. Drugs 2006; 66(13): 1752–4
Hanson GR, Li T-K. Public health implications of excessive alcohol consumption. JAMA 2003 Feb 26; 289(8): 1031–2
Rehm J, Gmel G, Sempos CT, et al. Alcohol-related morbidity and mortality. Alcohol Res Health 2003; 27(1): 39–51
Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Report prepared by the Lewin Group for the National Institute on Alcohol Abuse and Alcoholism, 2000. Based on estimates, analyses, and data reported in Harwood H, Fountain D and Livermore G. The economic costs of alcohol and drug abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services. NIH publication no. 98-4327. Rockville, (MD): National Institutes of Health, 1998 [online]. Available from URL: http://pubs.niaaa.nih.gov/publications/economic-2000/printing.htm [Accessed 2005 Nov 21]
Substance Abuse and Mental Health Services Administration. (2005). Results from the 2004 national survey on drug use and health: national findings. Rockville (MD): Office of Applied Studies,NSDUH Series H-28, DHHS Publication No. SMA 05-4062, 2005 Sep 8
National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician’s guide. 2005 edition [online]. Available from URL: http://pubs.niaaa.nih.gov/publications/practitioner/CliniciansGuide2005/guide.pdf [Accessed 2005 Nov 21]
Rohsenow DJ. What place does naltrexone have in the treatment of alcoholism? CNS Drugs 2004; 18(9): 547–60
Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004 Nov; 99(11): 1382–92
Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clinical Exp Res 2004; 28(7): 1051–9
Dean RL. The preclinical development of Medisorb® naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence. Front Biosci 2005 Jan; 10: 643–55
Department of Health and Human Services. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations: 26th edition. Cumulative supplement 07 July 2006 [online]. Available from URL: http://www.fda.gov/cder/orange/obcs.pdf [Accessed 2006 Sep 6]
Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of extended-release injectable naltrexone. Alcohol Clin Exp Res 2006; 30(3): 480–90
Alkermes, Inc. 380mg/vial Vivitrol™ (naltrexone for extended-release injectable suspension) [online]. Available from URL: http://www.alkermes.com/pdf/vivitrol%20PI.pdf [Accessed 2006 Apr 18]
Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of extended-release injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005 Apr; 293(13): 1617–25
O’Malley SS, Zweben A, Loewy J, et al. Abstinence and self-help participation outcomes with injectable long-acting naltrexone pharmacotherapy for alcohol dependence. 37th Annual Medical Scientific Conference of the American Society of Addiction Medicine; 2006 May 4–7; San Diego (CA)
Kranzler HR, Liou S, Loewy J, et al. Effect of long-acting injectable naltrexone on quality of life, [abstract no. NR832 plus poster]. American Psychiatric Association 2005 Annual Meeting: 2005 May 21–26; Atlanta (GA): 309
Gastfriend DR, Dong Q, Loewy J, et al. Durability of effect of long-acting injectable naltrexone [abstract no. NR280 plus poster]. American Psychiatric Association 2005 Annual Meeting; 2005 May 21–26; Atlanta (GA), 104
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209–23
Dr Kiefer has no conflicts of interest directly relevant to the content of this commentary.
Supported by grant K24 AA13736 from the National Institute on Alcohol Abuse and Alcoholism. Dr. Kranzler has received support for research and has served as a consultant or speaker for the following companies: Alkermes, Inc., Bristol-Myers Squibb Co., DrugAbuse Sciences, Forest Laboratories and Ortho-McNeil Pharmaceuticals.
Dr Siegel has no conflicts of interest directly relevant to this commentary.
Adapted and reproduced from Drugs; 66 (13): 1741–54. The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.
About this article
Cite this article
Harrison, T.S., Plosker, G.L. & Keam, S.J. Extended-Release Intramuscular Naltrexone in Alcohol Dependence in Adults: Profile Report. CNS Drugs 21, 83–87 (2007). https://doi.org/10.2165/00023210-200721010-00007
- Alcohol Dependence
- Heavy Drinking
- Injection Site Reaction